论文部分内容阅读
80例口服磺脲类降糖药血糖控制不理想的2型糖尿病患者随机分为甘精胰岛素加口服格列美脲片组(A组)和预混胰岛素组(B组),甘精胰岛素予睡前皮下注射胰岛素、口服格列美脲,预混胰岛素早晚餐前半皮下注射胰岛素。治疗12周。观察治疗前后空腹血糖、餐后2h血糖、糖化血红蛋白、空腹C肽、餐后C肽的变化。结果A组治疗后FPG(6.4±1.5)mmol/L,2hPG(8.8±1.5)mmol/L,HbAlc(6.8±0.7)%;B组治疗后FPG(6.4±1.1)mmol/L,2hPG(8.9±1.3)mmol/L,HbAlc(6.7±0.8)%,较治疗前差异有极显著性(P<0.01);但A组的低血糖事件明显少于B组(P<0.01);且A组治疗后C肽水平明显升高。结论甘精胰岛素联用格列美脲片治疗2型糖尿病的方案安全有效,简便易行,能减少低血糖事件的发生,且可能改善胰岛功能。
80 cases of oral sulfonylureas hypoglycemic control of type 2 diabetes patients with poor glycemic control were randomly divided into insulin glargine plus oral glimepiride tablets group (A group) and premixed insulin group (B group), insulin glargolide Subcutaneous injection of insulin at bedtime, oral glimepiride, premixed insulin, subcutaneous subcutaneous injection of insulin before breakfast and dinner. Treatment for 12 weeks. Fasting blood glucose, postprandial blood glucose 2h, glycosylated hemoglobin, fasting C-peptide and postprandial C-peptide were observed before and after treatment. Results FPG (6.4 ± 1.5) mmol / L, HbA1c (6.8 ± 0.7)% and FPG (6.4 ± 1.1) mmol / L and 2hPG ± 1.3) mmol / L and HbAlc (6.7 ± 0.8)% respectively, which were significantly higher than those before treatment (P <0.01), but the hypoglycemic events in group A were less than those in group B C-peptide levels were significantly elevated after treatment. Conclusion The combination of glargine and glimepiride in the treatment of type 2 diabetes is safe, effective, simple and easy, can reduce the occurrence of hypoglycaemia, and may improve the function of islets.